KPTI

Karyopharm Therapeutics Inc. (KPTI) | Rumor.io

Karyopharm Therapeutics

KPTI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,212

Bullish sentiment (50-day avg)38%

Price to earnings ratio-0.09

Market capitalization36.7M

Earnings per share-14.3

Dividend yield (TTM)—

Revenue (annual)146.1M

Net income (annual)-196M

Social

What share of all stock conversation is about KPTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Sep 11

Karyopharm Therapeutics Inc. (KPTI) has entered a forbearance agreement with lenders, delaying payments on $15.8 million in principal due by October 15.
The agreement allows the company to negotiate with lenders for further financial support or an equity raise, and to advance its myelofibrosis program.
KPTI's stock price has been affected, with a significant decline of 11% since the filing of the forbearance agreement, and some analysts are warning of a going-concern warning.

Generated by AI

Sentiment

Of the messages about KPTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	30%	27.27% -17.17	32.88% -25.11	47.14% -6.38
Bearish	70%	72.73% +17.17	67.12% +25.11	52.86% +6.38

Bullish· Aug 3

$KPTI is poised for a significant technical rebound after last Friday's session, and could potentially break above $2.10 to take off.
The stock has the potential to fly soon and is on its way to $3, with some traders even joking about its ability to do so with a little luck.
Despite a massive selloff, long-term buyers see opportunity in the steep discount and are advised to accumulate the dip and stay patient, as the stock's fundamentals remain strong.

Bearish· Sep 11

The company has a history of missing debt payments, with a recent $15.8 million term-loan payment missed, prompting a creditor forbearance pact and a $20 million preferred stock issuance.
The stock's price has been heavily influenced by short sellers, with many taking positions at the $1.80 break down and now facing a sell side liquidity squeeze.
The company's financial situation appears dire, with a possible 50% dilution of existing shares just to survive a few weeks, and a history of weak volume and strong red flags, making it a target for bears.

Generated by AI

Topics

Of the messages about KPTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	56.14%	78.54%
Technical Analysis	—	0%	38.6%	4.26%
Analysts	—	0%	5.26%	15.21%
Controversies	—	0%	0%	0.14%
Earnings	—	0%	0%	1.14%
Macro	—	0%	0%	0.71%

Earnings· May 10

Karyopharm Therapeutics Inc. (KPTI) misses earnings per share (EPS) estimates by $0.16.
KPTI beats revenue estimates by $7.40M.
KPTI reports FQ1 earnings of -$0.78 EPS and $10M in revenues.

Analysts· Aug 6

Karyopharm Therapeutics Inc. (KPTI) was downgraded by multiple analysts, including JPMorgan, RBC Capital, SVB Leerink, and HC Wainwright.
Analyst targets for KPTI were lowered by various firms, with some setting price targets as low as $6, while others maintained a buy rating with lower price targets.
The downgrades were largely due to concerns about the prospects of XPOVIO, a key product for Karyopharm Therapeutics Inc.

Announcements· Feb 26

Karyopharm Therapeutics Inc. (KPTI) announced a 1-for-15 stock split.
The stock split is effective as of the close of trading on a date to be determined.
The exact date for the stock split will be announced in a separate press release.

Technical Analysis· Feb 22

KPTI has been a range-bound stock, offering opportunities for low-risk, high-probability trades on both the long and short sides.
The stock's price action is predictable, with a load zone around $14.50-$14.70 and a sell zone around $17.
KPTI's 50-day moving average has moved below its 200-day moving average, indicating a downtrend since August 7, 2020.

Generated by AI

Community

Of the messages about KPTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	81.82%	43.48%	32.56%	57.6%
Newcomers	18.18%	56.52%	67.44%	42.4%

Regulars· Sep 11

Karyopharm Therapeutics has executed a forbearance agreement to delay payments on approximately $15.8 million in principal due, allowing time to negotiate with lenders for further financial support or equity raise.
The company has received $20M worth of preferred shares convertible into common stock at $1.62, granted to lenders to allow Karyopharm to survive until October.
The regulars are focused on the upcoming sNDA decision news, with some expecting a positive outcome, while others are concerned about the potential default and conspiracy theories surrounding the company's financial situation.

Newcomers· Aug 13

Newcomers are focusing on Karyopharm Therapeutics' (KPTI) myelofibrosis treatment and its potential for Q1 launch, with some speculating about the company's revenue estimates.
Investors are concerned about KPTI's debt levels and the need for cash, with some suggesting that the company's debt may be a major issue if it fails to secure Q1 approval for its myelofibrosis treatment.
The planned August submission of an sNDA for selinexor in combination with ruxolitinib in myelofibrosis is seen as a positive development, with the potential for KPTI's treatment to become the first approved combination therapy for patients with myelofibrosis.

Generated by AI

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

19d agoYahoo Finance

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...

26d agoYahoo Finance

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands […]

1mo agoYahoo Finance

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Detailed price information for Karyopharm Therapeut (KPTI-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program.

1mo agoYahoo! Finance Canada

Also Discussed

Investors talking about KPTI also mention

#	Name	Attention
1	MYOV - Myovant Sciences Ltd.	——
2	GTHX - G1 Therapeutics, Inc.	——
3	Heron Therapeutics, Inc.HRTX	0%+0
4	Prothena Corp PLCPRTA	0%0
5	TG Therapeutics Inc.TGTX	0.01%+0
6	Agios Pharmaceuticals, Inc.AGIO	0%0
7	BPMC - Blueprint Medicines Corporation	——
8	JNCE - Jounce Therapeutics, Inc.	——
9	MacroGenics Inc.MGNX	0%0
10	Puma Biotechnology, Inc.PBYI	0%0

Karyopharm Therapeutics Inc.

Healthcare
Biotechnology

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear export pathways, including selective inhibitor of nuclear export compounds designed to inhibit exportin 1 (XPO1). Its current portfolio centers on oncology, with marketed and late-stage programs addressing blood cancers and solid tumors. The company’s products and clinical development efforts are aimed at treating patients who need options across hematology and oncology settings, and its commercial activities support the availability of approved cancer therapies in the United States. Headquartered in Newton, Massachusetts, Karyopharm Therapeutics Inc. plays a specialized role in the biopharmaceutical market by advancing targeted treatments built around a distinct molecular mechanism.

Website

Location

85 Wells Avenue

Newton, MA, 02459-3298

United States

Social

What share of all stock conversation is about KPTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Sep 11

Karyopharm Therapeutics Inc. (KPTI) has entered a forbearance agreement with lenders, delaying payments on $15.8 million in principal due by October 15.
The agreement allows the company to negotiate with lenders for further financial support or an equity raise, and to advance its myelofibrosis program.
KPTI's stock price has been affected, with a significant decline of 11% since the filing of the forbearance agreement, and some analysts are warning of a going-concern warning.

Generated by AI

Sentiment

Of the messages about KPTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	30%	27.27% -17.17	32.88% -25.11	47.14% -6.38
Bearish	70%	72.73% +17.17	67.12% +25.11	52.86% +6.38

Bullish· Aug 3

$KPTI is poised for a significant technical rebound after last Friday's session, and could potentially break above $2.10 to take off.
The stock has the potential to fly soon and is on its way to $3, with some traders even joking about its ability to do so with a little luck.
Despite a massive selloff, long-term buyers see opportunity in the steep discount and are advised to accumulate the dip and stay patient, as the stock's fundamentals remain strong.

Bearish· Sep 11

The company has a history of missing debt payments, with a recent $15.8 million term-loan payment missed, prompting a creditor forbearance pact and a $20 million preferred stock issuance.
The stock's price has been heavily influenced by short sellers, with many taking positions at the $1.80 break down and now facing a sell side liquidity squeeze.
The company's financial situation appears dire, with a possible 50% dilution of existing shares just to survive a few weeks, and a history of weak volume and strong red flags, making it a target for bears.

Generated by AI

Topics

Of the messages about KPTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	56.14%	78.54%
Technical Analysis	—	0%	38.6%	4.26%
Analysts	—	0%	5.26%	15.21%
Controversies	—	0%	0%	0.14%
Earnings	—	0%	0%	1.14%
Macro	—	0%	0%	0.71%

Earnings· May 10

Karyopharm Therapeutics Inc. (KPTI) misses earnings per share (EPS) estimates by $0.16.
KPTI beats revenue estimates by $7.40M.
KPTI reports FQ1 earnings of -$0.78 EPS and $10M in revenues.

Analysts· Aug 6

Karyopharm Therapeutics Inc. (KPTI) was downgraded by multiple analysts, including JPMorgan, RBC Capital, SVB Leerink, and HC Wainwright.
Analyst targets for KPTI were lowered by various firms, with some setting price targets as low as $6, while others maintained a buy rating with lower price targets.
The downgrades were largely due to concerns about the prospects of XPOVIO, a key product for Karyopharm Therapeutics Inc.

Announcements· Feb 26

Karyopharm Therapeutics Inc. (KPTI) announced a 1-for-15 stock split.
The stock split is effective as of the close of trading on a date to be determined.
The exact date for the stock split will be announced in a separate press release.

Technical Analysis· Feb 22

KPTI has been a range-bound stock, offering opportunities for low-risk, high-probability trades on both the long and short sides.
The stock's price action is predictable, with a load zone around $14.50-$14.70 and a sell zone around $17.
KPTI's 50-day moving average has moved below its 200-day moving average, indicating a downtrend since August 7, 2020.

Generated by AI

Community

Of the messages about KPTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	81.82%	43.48%	32.56%	57.6%
Newcomers	18.18%	56.52%	67.44%	42.4%

Regulars· Sep 11

Karyopharm Therapeutics has executed a forbearance agreement to delay payments on approximately $15.8 million in principal due, allowing time to negotiate with lenders for further financial support or equity raise.
The company has received $20M worth of preferred shares convertible into common stock at $1.62, granted to lenders to allow Karyopharm to survive until October.
The regulars are focused on the upcoming sNDA decision news, with some expecting a positive outcome, while others are concerned about the potential default and conspiracy theories surrounding the company's financial situation.

Newcomers· Aug 13

Newcomers are focusing on Karyopharm Therapeutics' (KPTI) myelofibrosis treatment and its potential for Q1 launch, with some speculating about the company's revenue estimates.
Investors are concerned about KPTI's debt levels and the need for cash, with some suggesting that the company's debt may be a major issue if it fails to secure Q1 approval for its myelofibrosis treatment.
The planned August submission of an sNDA for selinexor in combination with ruxolitinib in myelofibrosis is seen as a positive development, with the potential for KPTI's treatment to become the first approved combination therapy for patients with myelofibrosis.

Generated by AI

Karyopharm Therapeutics

Social

Sep 11

Bullish· Aug 3

Bearish· Sep 11

Earnings· May 10

Analysts· Aug 6

Announcements· Feb 26

Technical Analysis· Feb 22

Regulars· Sep 11

Newcomers· Aug 13

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

Also Discussed

Karyopharm Therapeutics Inc.

Company Information

Location

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

Also Discussed

Social

Sep 11

Bullish· Aug 3

Bearish· Sep 11

Earnings· May 10

Analysts· Aug 6

Announcements· Feb 26

Technical Analysis· Feb 22

Regulars· Sep 11

Newcomers· Aug 13